 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Prednisone for Rheumatoid Arthritis
1 January 2002 | Volume 136 Issue 1 | Page S72
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." It is in the 1 January 2002 issue of Annals of Internal Medicine (volume 136, pages 1-12). The authors are AA van Everdingen, JWG Jacobs, DR Siewertsz van Reesema, and JWJ Bijlsma.
What is the problem and what is known about it so far?
Rheumatoid arthritis (RA) is a chronic disease that causes painful, swollen, and deformed joints. It is caused by inflammation of the tissue linings (membranes) of joints and most often affects many small joints of the hands and feet, but may develop in any joint. People with RA usually have chronic joint pain and stiffness. There is no cure for RA, but signs and symptoms can be treated. Persistent arthritis is painful and destroys joints, and about 1 in 10 persons with RA may eventually become severely disabled from joint destruction. Several powerful drugs, named disease-modifying antirheumatic drugs (DMARDs), reduce both symptoms and the risk for permanent joint damage. Other drugs, known as glucocorticoids (prednisone), reduce inflammation and improve symptoms. Recent studies suggest that prednisone also can help prevent joint damage in patients who are taking DMARDs. Whether prednisone prevents joint damage in patients who do not use DMARDs is unclear.
Why did the researchers do this particular study?
To see whether low doses of prednisone prevent joint damage in adults who have early active RA but have little joint damage and use no DMARDs.
Who was studied?
81 adults who had had RA for less than 1 year. None had been treated with DMARDs. Most (64%) were women, and the average age was about 60 years.
How was the study done?
Patients were randomly assigned to receive prednisone (10 mg daily) or placebo (dummy pill) for 2 years. Neither the patients nor their physicians were told who got prednisone or dummy pills. To measure the effect of treatment, the authors assessed joint symptoms and x-rayed the joints every 6 months.
What did the researchers find?
At 6 months, patients who took prednisone had fewer symptoms (joint stiffness, swelling, and tenderness) and better grip strength. During the study, they also used fewer additional therapies (for example, nonsteroidal anti-inflammatory drugs) than patients given dummy pills. One and 2 years after starting treatment, x-rays showed less joint damage with prednisone than with dummy pills. Five patients given prednisone and 2 patients given placebo developed fractures in the small bones of their backs.
What were the limitations of the study?
This study was started almost 10 years ago, before doctors routinely used DMARDs for all patients with RA. Also, patients in this study received only calcium to prevent thinning of their bones and fractures. Using newer therapies in addition to calcium might prevent fractures related to prednisone. Finally, the authors did not test the effect of even lower doses of prednisone, such as 2.5 or 5 mg daily.
What are the implications of the study?
Prednisone in dosages of 10 mg daily improves symptoms in patients with early active RA and prevents progression of joint damage, but it also increases risk for bone fractures.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E H S Choy, C M Smith, V Farewell, D Walker, A Hassell, L Chau, D L Scott, and for the CARDERA (Combination Anti-Rheumatic Drugs Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis Ann Rheum Dis, May 1, 2008; 67(5): 656 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Iikuni, E. Inoue, E. Tanaka, M. Hara, T. Tomatsu, N. Kamatani, and H. Yamanaka Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis Rheumatology, April 1, 2008; 47(4): 519 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Aletaha, V Strand, J S Smolen, and M M Ward Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results Ann Rheum Dis, February 1, 2008; 67(2): 238 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. M. Wasko, H. B. Hubert, V. B. Lingala, J. R. Elliott, M. E. Luggen, J. F. Fries, and M. M. Ward Risk of Diabetes in Patients With Rheumatoid Arthritis Taking Hydroxychloroquine Reply JAMA, November 28, 2007; 298(20): 2369 - 2370. [Full Text] [PDF]
|
|
|
|
|
|
J W J Bijlsma and M E Weinblatt Optimal use of methotrexate: the advantages of tight control Ann Rheum Dis, November 1, 2007; 66(11): 1409 - 1410. [Full Text] [PDF]
|
|
|
|
|
|
J. Grisar, D. Aletaha, C. W Steiner, T. Kapral, S. Steiner, M. Saemann, I. Schwarzinger, B. Buranyi, G. Steiner, and J. S Smolen Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy Ann Rheum Dis, October 1, 2007; 66(10): 1284 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fardet, J. Cabane, A. Kettaneh, C. Lebbe, and A. Flahault Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome Rheumatology, July 1, 2007; 46(7): 1102 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Scott Early rheumatoid arthritis Br. Med. Bull., May 31, 2007; (2007) ldm011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Baron, I. Boutron, B. Giraudeau, and P. Ravaud Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis Ann Rheum Dis, May 1, 2007; 66(5): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Combe, R Landewe, C Lukas, H D Bolosiu, F Breedveld, M Dougados, P Emery, G Ferraccioli, J M W Hazes, L Klareskog, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis, January 1, 2007; 66(1): 34 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Capellino, B Riepl, L Rauch, P Angele, M Cutolo, and R H Straub Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis, January 1, 2007; 66(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Combination therapy for early rheumatoid arthritis DTB, November 1, 2006; 44(11): 81 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S M M Verstappen, J N Hoes, E J ter Borg, J W J Bijlsma, A A M Blaauw, G A van Albada-Kuipers, C van Booma-Frankfort, J W G Jacobs, and on behalf of the Utrecht Rheumatoid Arthritis Coho Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy Ann Rheum Dis, November 1, 2006; 65(11): 1506 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z N Jahangier, K M G Jacobs, J W J Bijlsma, and F P J G Lafeber Radiation synovectomy with yttrium-90 for persisting arthritis has direct harmful effects on human cartilage that cannot be prevented by co-administration of glucocorticoids: an in vitro study Ann Rheum Dis, October 1, 2006; 65(10): 1384 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Morrison and H. A. Capell Corticosteroids in the management of early and established rheumatoid disease Rheumatology, September 1, 2006; 45(9): 1058 - 1061. [Full Text] [PDF]
|
|
|
|
|
|
D. Aeberli, M. Leech, and E. F. Morand Macrophage migration inhibitory factor and glucocorticoid sensitivity Rheumatology, August 1, 2006; 45(8): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Saha, R. Siva, C. E. Brightling, and I. D. Pavord COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. Eur. Respir. J., April 1, 2006; 27(4): 863 - 865. [Full Text] [PDF]
|
|
|
|
|
|
J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Aletaha and M M Ward Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials Ann Rheum Dis, February 1, 2006; 65(2): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Matthay and C. S. Calfee Therapeutic Value of a Lung Protective Ventilation Strategy in Acute Lung Injury Chest, November 1, 2005; 128(5): 3089 - 3091. [Full Text] [PDF]
|
|
|
|
|
|
E H Choy, G H Kingsley, B Khoshaba, N Pipitone, D L Scott, and the Intramuscular Methylprednisolone Study Group A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs Ann Rheum Dis, September 1, 2005; 64(9): 1288 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Haugeberg, A. Strand, T. K. Kvien, and J. R. Kirwan Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis: Results From a Randomized Placebo-Controlled Trial Arch Intern Med, June 13, 2005; 165(11): 1293 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pisu, N. James, S. Sampsel, and K. G. Saag The cost of glucocorticoid-associated adverse events in rheumatoid arthritis Rheumatology, June 1, 2005; 44(6): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Kirwan, M Boers, H Capell, J Hunter, R Madhok, E Morrison, J Larkin, and on behalf of the WOSERACT group Low dose prednisolone for treatment of RA * Authors' reply Ann Rheum Dis, November 1, 2004; 63(11): 1533 - 1534. [Full Text] [PDF]
|
|
|
|
|
|
H A Capell, R Madhok, J A Hunter, D Porter, E Morrison, J Larkin, E A Thomson, R Hampson, and F W Poon Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial Ann Rheum Dis, July 1, 2004; 63(7): 797 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. O'Dell Therapeutic Strategies for Rheumatoid Arthritis N. Engl. J. Med., June 17, 2004; 350(25): 2591 - 2602. [Full Text] [PDF]
|
|
|
|
|
|
P P Geusens, R N J de Nijs, W F Lems, R F J M Laan, A Struijs, T P van Staa, and J W J Bijlsma Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology Ann Rheum Dis, March 1, 2004; 63(3): 324 - 325. [Full Text] [PDF]
|
|
|
|
|
|
F C Breedveld, P Emery, E Keystone, K Patel, D E Furst, J R Kalden, E W St Clair, M Weisman, J Smolen, P E Lipsky, et al. Infliximab in active early rheumatoid arthritis Ann Rheum Dis, February 1, 2004; 63(2): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J W J Bijlsma, M Boers, K G Saag, and D E Furst Glucocorticoids in the treatment of early and late RA Ann Rheum Dis, November 1, 2003; 62(11): 1033 - 1037. [Full Text] [PDF]
|
|
|
|
|
|
M Cutolo, B Seriolo, C Craviotto, C Pizzorni, and A Sulli Circadian rhythms in RA Ann Rheum Dis, July 1, 2003; 62(7): 593 - 596. [Full Text] [PDF]
|
|
|
|
|
|
H Forsblad d'Elia, A Larsen, E Waltbrand, G Kvist, D Mellstrom, T Saxne, C Ohlsson, E Nordborg, and H Carlsten Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis Ann Rheum Dis, July 1, 2003; 62(7): 617 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Bae, M. Corzillius, K. M. Kuntz, and M. H. Liang Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis Rheumatology, January 1, 2003; 42(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pincus, G. Ferraccioli, T. Sokka, A. Larsen, R. Rau, I. Kushner, and F. Wolfe Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review Rheumatology, December 1, 2002; 41(12): 1346 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Weisman Newly diagnosed rheumatoid arthritis Ann Rheum Dis, April 1, 2002; 61(4): 287 - 289. [Full Text] [PDF]
|
|
|
|
 |
|
 Low-Dose Steroids to Prevent RA Disease Progression? Journal Watch Gastroenterology, March 12, 2002; 2002(312): 13 - 13. [Full Text]
|
|
|
|
 |
|
 Low-Dose Steroids to Prevent RA Disease Progression? Journal Watch (General), January 22, 2002; 2002(122): 1 - 1. [Full Text]
|
|
|
|
 |
|
 T. Pincus, T. Sokka, and C. M. Stein Are Long-Term Very Low Doses of Prednisone for Patients with Rheumatoid Arthritis as Helpful as High Doses Are Harmful? Ann Intern Med, January 1, 2002; 136(1): 76 - 78. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
